CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Index values follow a defined daily schedule so investors know when to expect updates. This brief explains the publication times and how to use the data in your investing routine.
21,512 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
AI is reshaping business, and a few durable names stand to benefit for years. Here are three artificial intelligence ...
Ford bets on human experience to guide AI, tapping 350 veteran engineers to steer its technology push as recalls and ...
Pfizer may be sitting on a hidden GLP-1 opportunity. This article breaks down why the company could prove to be an un...
Australian regulators have activated full Travel Rule checks for crypto transfers. Exchanges and other service provid...
A Scattered Spider suspect extradited to the US shines a light on how cross-border cybercrime prosecutions unfold. Th...
A 34% year-to-date drop has investors wondering if Zscaler can stage a comeback. This deep dive breaks down the catal...
Memory demand tied to AI and data centers has Micron at a pivotal moment. This guide breaks down whether micron stock...
A viral post shows a budget-friendly way for a family of five to eat at Chick-Fil-A for under $45 by pairing nuggets ...
Investors wonder about the path ahead for Lucid stock. This guide lays out three scenarios, the key drivers, and conc...
Mastercard posts strong Q1 2026 results with rising services and margins, while PayPal signals a flat-to-down 2026. T...
A high-profile tech founder says America’s universities aren’t teaching practical engineering, risking a talent gap a...